Propranolol – Kodiac biolabs

Plain-language summaryIntrigue 73 / 100

Propranolol (Inderal) is the first commercially successful beta-blocker, developed by James Black at ICI and approved by the FDA in 1967. Black’s work on it earned him the Nobel Prize and reshaped cardiovascular medicine. It blocks both subtypes of beta-adrenergic receptor, dampening the heart’s response to adrenaline as well as the bronchial and metabolic effects. Beyond its many cardiovascular uses, it has a substantial second life in psychiatry and neurology: it is the standard prescription for performance anxiety (one or two tablets before public speaking blunts the heart-pounding and tremor without affecting cognition), is first-line for migraine prevention, and has been studied for trauma memory reconsolidation in PTSD. Lipophilic enough to cross into the brain, which contributes to both its therapeutic and side effects. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

41/100

Historical cornerstone with almost no remaining research novelty; valuable as a canonical non-selective beta-blocker probe

Look, propranolol is one of the most consequential drugs in the history of pharmacology. James Black’s Nobel Prize was built partly on it. And yet, as a research target in 2026, it’s almost entirely spent. That’s the tension the score reflects, and it’s not a close call.

The cardiovascular evidence base is airtight. Hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor — six approved indications and decades of replicated RCTs sitting behind each of them. The pharmacokinetics have been characterized exhaustively: non-selective beta-1 and beta-2 blockade, 3-to-6 hour half-life, high lipophilicity giving CNS penetration that hydrophilic competitors like atenolol and nadolol simply lack. Those properties earned it permanent status as the reference non-selective beta-blocker. That reference-compound identity is essentially its only remaining research value — real, but narrow.

The most interesting live research angle is the PTSD memory reconsolidation work, and we want to be honest about what that actually is. The mechanistic logic is genuinely clever: noradrenergic signaling in the basolateral amygdala is required for fear memory reconsolidation, so blocking beta-adrenergic receptors during a deliberate recall event should attenuate reconsolidation and weaken the traumatic memory. Pitman’s Harvard MGH group published the original proof-of-concept in 2002. Alain Brunet’s Montreal lab has been the most persistent investigator, including a 2018 randomized trial in PTSD patients showing meaningful symptom reduction. The signal is real. But the 2019 Cochrane review found the evidence base insufficient, effect sizes across studies are modest, and its been 24 years since the founding paper. Calling this novel would be a stretch.

The novelty problem is fundamental. Beta-adrenergic blockade has been understood mechanistically since the 1960s. No new chemistry, no new mechanisms, no structural innovations. For reconsolidation paradigms specifically, metoprolol covers most of the same ground, and timolol is another option with similar CNS access. Propranolol has first-mover advantage in this niche and a denser associated literature, but its not uniquely irreplaceable in most bench designs.

What we like: the translational track record is definitive, and for performance anxiety studies, adrenergic probe work, or reconsolidation paradigms, its the right tool and the right reference. What we don’t like: the mechanism is fully characterized, the novelty is gone, and the questions propranolol can uniquely answer are getting fewer every year. A serious investigator building a new research program around propranolol in 2026 would need a very specific reason. This is a historical cornerstone, not a frontier compound.

Novelty: 10
Mechanism promise: 20
In-category differentiation: 30
Evidence quality: 80
Translational signal: 80
Research bench value: 50

Rationale Propranolol scores extremely low on novelty and mechanism — it’s a 1967 drug with single-receptor, fully-characterized pharmacology and no new chemistry — but pulls evidence and translational scores high owing to its approved-drug status across six indications and 60 years of clinical use; the PTSD memory reconsolidation angle is the most interesting current research use case, but Pitman’s foundational work is 24 years old and replication remains mixed, preventing a meaningful novelty rescue.

Non-selective beta-adrenergic antagonist

A non-selective beta-adrenergic antagonist; the first beta-blocker, repurposed for performance anxiety and migraine prophylaxis.

Abstract

Propranolol (1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; CAS 525-66-6; molecular formula C16H21NO2; molecular weight 259.34) is a non-selective beta-adrenergic antagonist developed by James Black at ICI and approved by the FDA in 1967 under the trade name Inderal. The compound is the first commercially successful beta-blocker, foundational to modern cardiovascular pharmacology. Beta-1 affinity is approximately equal to beta-2 affinity (non-selective). Plasma half-life is 3 to 6 hours; the lipophilic structure produces high CNS penetration, distinguishing propranolol from hydrophilic beta-blockers (atenolol, nadolol) for indications requiring central effect. Approved indications include hypertension, angina, atrial fibrillation, migraine prophylaxis, essential tremor, and hypertrophic cardiomyopathy. Off-label use is extensive: performance anxiety (most common psychiatric indication), PTSD memory reconsolidation, akathisia, hyperthyroid tachycardia. The 5-HT receptor partial agonism (weak) was a former curiosity but is not clinically meaningful at standard doses. Used as the canonical non-selective beta-blocker reference compound.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-256Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.